Minimal residual disease is “a credible intermediate endpoint” for some patients with newly diagnosed acute myeloid leukemia, researchers report.
Although minimal residual disease (MRD) has emerged as a valuable prognostic marker across several hematological malignancies, its use in chronic lymphocytic leukemia (CLL) is mostly limited to ...
Five hundred forty-two specimens of 150 children enrolled in the AML-Berlin-Frankfurt-Muenster (BFM) 98 study were analyzed by four-color immunophenotyping at up to four predefined time points during ...
Time-limited treatment with a three-drug combination for relapsed/refractory chronic lymphocytic leukemia (CLL) produced long-term undetectable residual disease in more than 90% of patients, updated ...
The press release below was prepared by the American Association for Cancer Research. View the original here. Next-generation sequencing for minimal residual disease was highly sensitive and more ...
In a large analysis presented at ASH's annual meeting, researchers reported that patients' MRD status after intensive chemo can predict their survival.
Why minimal residual disease testing is the "gold standard" for some patients and providers. When Michael Ray went to his doctor for an annual checkup two years ago, he felt fine. But the bloodwork ...
MRD negativity post-chemotherapy strongly predicts improved overall survival in AML, with a significant reduction in mortality risk. The study suggests MRD could serve as an earlier surrogate endpoint ...
Purpose Monitoring of residual disease (RD) by flow cytometry in childhood acute myeloid leukemia (AML) may predict outcome. However, the optimal time points for investigation, the best antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback